John MD - Lixte Biotechnology President, Founder

LIXT Stock  USD 1.91  0.04  2.05%   

Insider

John MD is President, Founder of Lixte Biotechnology Holdings
Age 87
Address 680 East Colorado Boulevard, Pasadena, CA, United States, 91101
Phone631 830 7092
Webhttps://lixte.com

Lixte Biotechnology Management Efficiency

The company has return on total asset (ROA) of (0.8733) % which means that it has lost $0.8733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6333) %, meaning that it created substantial loss on money invested by shareholders. Lixte Biotechnology's management efficiency ratios could be used to measure how well Lixte Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.24 in 2024. Return On Capital Employed is likely to drop to -1.34 in 2024. Change To Liabilities is likely to gain to about 106.3 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 290.7 K in 2024.
Lixte Biotechnology Holdings currently holds 313.86 K in liabilities with Debt to Equity (D/E) ratio of 0.16, which may suggest the company is not taking enough advantage from borrowing. Lixte Biotechnology has a current ratio of 14.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lixte Biotechnology's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Gordon JDQuoin Pharmaceuticals Ltd
60
Frank KondradNeurobo Pharmaceuticals
N/A
Deepika PharmDPmv Pharmaceuticals
48
MD BAPasithea Therapeutics Corp
76
MD DrScAllarity Therapeutics
81
Courtney DuganOlema Pharmaceuticals
N/A
Desiree DDSPassage Bio
N/A
Jeffrey MecklerIndaptus Therapeutics
57
Kinney HornOlema Pharmaceuticals
50
Steen KnudsenAllarity Therapeutics
63
Winston MBAPmv Pharmaceuticals
48
David MackPmv Pharmaceuticals
62
Simona KingPassage Bio
52
Yassine BendiabdallahPasithea Therapeutics Corp
40
David MylesOlema Pharmaceuticals
61
Caryn ParlavecchioScholar Rock Holding
52
James FosterVirax Biolabs Group
39
MBA MDScholar Rock Holding
57
MSc MBAPassage Bio
55
Professor MDAllarity Therapeutics
67
Daniel SchneidermanPasithea Therapeutics Corp
46
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in Pasadena, California. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. Lixte Biotechnology Holdings (LIXT) is traded on NASDAQ Exchange in USA. It is located in 680 East Colorado Boulevard, Pasadena, CA, United States, 91101 and employs 3 people. Lixte Biotechnology is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Lixte Biotechnology Leadership Team

Elected by the shareholders, the Lixte Biotechnology's board of directors comprises two types of representatives: Lixte Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lixte. The board's role is to monitor Lixte Biotechnology's management team and ensure that shareholders' interests are well served. Lixte Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lixte Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Bastiaan MSc, CEO President
Johannes MD, Chief Officer
James MD, Chief Officer
Robert Weingarten, VP CFO
Eric JD, VP COO
John MD, President, Founder

Lixte Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lixte Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.